BaFin initiates probe into Dermapharm annual financial statements

Germany's financial regulator, BaFin, is investigating Dermapharm over potential accounting irregularities involving a double-digit million euro receivable. The probe creates uncertainty regarding the company's financial reporting accuracy and potential future restatements.